

1. Palomaki GE, Knight GJ, Ashwood ER, Best RG, Haddow JE. Screening for down syndrome in the United States: results of surveys in 2011 and 2012. *Arch Pathol Lab Med.* 2013;137(7):921-926.
2. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. *Obstet Gynecol.* 2007;109(1):217-227.
3. Nussbaum RL, McInnes RR, Willard HF. Principles of clinical cytogenetics and genome analysis. *Thompson & Thompson Genetics in Medicine.* Philadelphia: Oxford Saunders; 2015:57-74.
4. Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. *Obstet Gynecol.* 2016;127(5):e108-122.
5. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. *N Engl J Med.* 2014;370(9):799-808.
6. Benn P, Curnow KJ, Chapman S, Michalopoulos SN, Hornberger J, Rabinowitz M. An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population. *PLoS One.* 2015;10(7):e0132313.
7. Fairbrother G, Burigo J, Sharon T, Song K. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. *J Matern Fetal Neonatal Med.* 2016;29(7):1160-1164.
8. Walker BS, Nelson RE, Jackson BR, Grenache DG, Ashwood ER, Schmidt RL. A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States. *PLoS One.* 2015;10(7):e0131402.
9. Practice Bulletin No. 163: Screening for Fetal Aneuploidy. *Obstet Gynecol.* 2016;127(5):979-981.
10. Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. *Prenat Diagn.* 2015;35(8):725-734.
11. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. *Genet Med.* 2016;doi: 10.1038/gim.2016.97.
12. Taneja PA, Snyder HL, de Feo E, et al. Noninvasive prenatal testing in the general obstetric population: clinical performance and counseling considerations in over 85,000 cases. *Prenat Diagn.* 2016;36(3):237-243.
13. Illumina. Analytical Validation of the veriFi® prenatal test: Enhanced Test Performance for Detecting Trisomies 21, 18, and 13 and the Option for Classification of Sex Chromosome Status. *Illumina White Paper.* 2012.
14. Platt LD, Janicki MB, Prosen T, et al. Impact of noninvasive prenatal testing in regionally dispersed medical centers in the United States. *Am J Obstet Gynecol.* 2014;211(4):368.e361-367.
15. Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, Abuhamad AZ. Association of combined first-trimester screen and noninvasive prenatal testing on diagnostic procedures. *Obstet Gynecol.* 2014;123(6):1303-1310.
16. Gardner RJM, Sutherland GR, Schaffer LG. *Chromosome abnormalities and genetic counseling.* 4th ed. New York, NY: Oxford University Press; 2012.
17. Jones KL, Jones MC, Campo MD. *Smith's Recognizable Patterns of Human Malformation.* 7th ed. Philadelphia, PA: Elsevier Health Sciences/Saunders; 2013.
18. Nagaoka SI, Hassold TJ, Hunt PA. Human aneuploidy: mechanisms and new insights into an age-old problem. *Nat Rev Genet.* 2012;13(7):493-504.
19. Levy B, Sigurjonsson S, Pettersen B, et al. Genomic imbalance in products of conception: single-nucleotide polymorphism chromosomal microarray analysis. *Obstet Gynecol.* 2014;124(2 Pt 1):202-209.
20. Gardner RJM, Sutherland GR, Shaffer LG. Parental age counseling and screening for fetal trisomy. *Chromosome abnormalities and genetic counseling.* 4 ed: Oxford University Press; 2012:403-416.
21. Hamilton BE, Martin JA, Osterman MJK, Curtin SC, Mathews TJ. Births: Final Data for 2014. Vol 642015.
22. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. *N Engl J Med.* 2005;353(19):2001-2011.
23. Shah FT, French KS, Osann KE, Bocian M, Jones MC, Korty L. Impact of Cell-Free Fetal DNA Screening on Patients' Choice of Invasive Procedures after a Positive California Prenatal Screen Result. *J Clin Med.* 2014;3(3):849-864.
24. Breathnach FM, Malone FD, Lambert-Messerlian G, et al. First- and second-trimester screening: detection of aneuploidies other than Down syndrome. *Obstet Gynecol.* 2007;110(3):651-657.
25. Tul N, Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. *Prenat Diagn.* 1999;19(11):1035-1042.

26. Mayo Clinic. Chorionic villus sampling. Risks. 2015. Accessed September 13, 2016, from <http://www.mayoclinic.org/tests-procedures/chorionic-villus-sampling/basics/risks/prc-20013566>.
27. Mayo Clinic. Amniocentesis. Risks. 2015. Accessed September 13, 2016, from <http://www.mayoclinic.org/tests-procedures/amniocentesis/basics/risks/prc-20014529>.
28. Rava RP, Srinivasan A, Sehnert AJ, Bianchi DW. Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. *Clin Chem*. 2013;60(1):243-250.
29. Brar H, Wang E, Struble C, Musci TJ, Norton ME. The fetal fraction of cell-free DNA in maternal plasma is not affected by a priori risk of fetal trisomy. *J Matern Fetal Neonatal Med*. 2013;26(2):143-145.
30. Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. *Prenat Diagn*. 2013;33(7):667-674.
31. Sehnert AJ, Rhees B, Comstock D, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. *Clin Chem*. 2011;57(7):1042-1049.
32. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. *Obstet Gynecol*. 2012;119(5):890-901.
33. Bianchi DW, Rava RP, Sehnert AJ. DNA sequencing versus standard prenatal aneuploidy screening. *N Engl J Med*. 2014;371(6):578.
34. Fosler L, Winters P, Jones KW, et al. Aneuploidy Screening Using Noninvasive Prenatal Testing in Twin Pregnancies. *Ultrasound Obstet Gynecol*. 2016;doi:10.1002/uog.15964.
35. Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. *Prenat Diagn*. 2013;33(6):569-574.17
36. Pergament E, Cuckle H, Zimmermann B, et al. Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Screening in a High-Risk and Low-Risk Cohort. *Obstet Gynecol*. 2014;124(2 Pt 1):210-218.
37. Juneau K, Bogard PE, Huang S, et al. Microarray-based cell-free DNA analysis improves noninvasive prenatal testing. *Fetal Diagn Ther*. 2014;36(4):282-286.
38. Curnow KJ, Wilkins-Haug L, Ryan A, et al. Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism-based noninvasive prenatal test. *Am J Obstet Gynecol*. 2015;212(1):79 e71-79.
39. Natera. Panorama. Common questions. Accessed September 29, 2016, from <http://www.natera.com/panorama-test/common-questions>.
40. Illumina. veriFi Prenatal Test. Physician Brochure. Accessed September 29, 2016 from http://www.illumina.com/content/dam/illumina-marketing/documents/applications/reproductive-health/22336_LB_0013_G_Physician_Brochure.pdf.
41. Ryan A, Hunkapiller N, Banjevic M, et al. Validation of an Enhanced Version of a Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Test for Detection of Fetal Aneuploidies. *Fetal Diagn Ther*. 2016;doi:10.1159/000442931.
42. Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA Analysis for Noninvasive Examination of Trisomy. *N Engl J Med*. 2015;372(17):1589-1597.
43. Dar P, Curnow KJ, Gross SJ, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based non-invasive prenatal aneuploidy testing. *Am J Obstet Gynecol*. 2014;211(5):527.e521-517.
44. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. *BMJ*. 2011;342:c7401.
45. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. *Am J Obstet Gynecol*. 2011;204(3):205.e201-211.
46. Taneja PA, Prosen TL, de Feo E, et al. Fetal aneuploidy screening with cell-free DNA in late gestation. *J Matern Fetal Neonatal Med*. 2016;doi:10.3109/14767058.2016.1172566(doi:10.3109/14767058.2016.1172566):1-5.
47. Snyder HL, Curnow KJ, Bhatt S, Bianchi DW. Follow-up of multiple aneuploidies and single monosomies detected by noninvasive prenatal testing: implications for management and counseling. *Prenat Diagn*. 2016;36(3):203-209.
48. Data calculations on file. Illumina, Inc. 2016.

49. Martin JA, Hamilton BE, Osterman MLK. Three Decades of Twin Births in the United States, 1980–2009. Hyattsville, MD: National Center for Health Statistics: CDC; 2012.
50. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. *BJOG*. 2003;110(3):281-286.
51. Chudova DI, Sehnert AJ, Bianchi DW. Copy-number variation and false positive prenatal screening results. *N Engl J Med*. 2016;375(1):97-98.
52. Garfield SS, Armstrong BA. Clinical and Cost Consequences of Incorporating a Novel Non-Invasive Prenatal Test into the Diagnostic Pathway for Fetal Trisomies. *J Manag Care Med*. 2012;15(2):34-41.
53. Committee Opinion No. 640: Cell-free DNA Screening for Fetal Aneuploidy. *Obstet Gynecol*. 2015;126(3):e31-37.
54. Society for Maternal Fetal Medicine. SMFM Statement on Cell-Free DNA Screening. Accessed September 16, 2016, from <https://www.smfm.org/publications/193-cell-free-dna-screening>.
55. Gekas J, Rodrigue M, Nshimyumukiza L, Reinharz D. Failure Rate May Significantly Impact the Cost Effectiveness of the Technology Used in Down Syndrome Noninvasive Prenatal Screening Programs (Abstract 641). Poster presented at ACMG Annual Clinical Genetics Meeting; 2016; Tampa, FL.
56. Blue Cross Blue Shield Association. *Technology Evaluation Center Assessment. Sequencing-based tests to determine fetal Down syndrome (trisomy 21) from maternal plasma DNA*. April 2013.
57. Blue Cross Blue Shield Association. *Technology Evaluation Center Assessment. Noninvasive prenatal cell-free fetal DNA-based screening for aneuploidies other than trisomy 21*. December 2014.
58. Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545. American College of Obstetricians and Gynecologists. *Obstet Gynecol*. 2012;120(6):1532-1534.
59. Devers PL, Cronister A, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. *J Genet Couns*. 2013;22(3):291-295.
60. Benn P, Borrell A, Cuckle H, et al. Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. *Prenat Diagn*. 2012;32(1):1-2.